Malignant tumors of the eye and its adnexa (C69) relates to rare tumors. Until 2011, this group of tumors was not included to the official cancer report in Russia.Purpose: to investigate the incidence of malignant tumors of eye and its adnexa (C69) in the population of St. Petersburg, to consider the dynamics of a complex of analytical indicators. Standard methods of statistical analysis, state reporting materials and data from the St. Petersburg Population Cancer Register were used. Malignant tumors of the eye and its adnexa (С69) were started to be officially registered only from 2011 onwards, however not in full as only Form 7 that allows to calculate morbidity was filled in. Other information could be obtained from the databases of the Population Cancer Registers (PRR), organized in the country in the late 90’s. Each year, more than 1,000 thousand (e.g.1977–2017 year) cases of malignant tumors of eye and its adnexa (С69) are detected in the whole country. In 2011, 925 cases were diagnosed. In Russia, the crude rate of malignant tumors of the eye and its adnexa (С69) has increased from 2011 to 2017 years from 0.65/100,000 in 2011 to 0.73/100,000 in 2017, respectively, +12.3 % (both sexes), standardized, eliminating the difference in the age composition of the population, remained almost unchanged –0.54 0/0000 and 0.53 0/0000. The standardized incidence rate in men of malignant tumors of eye and its adnexa (С69) in 2017 was 0.58 0/0000, women –0.49 0/0000. The state reporting for malignant tumors of eye and its adnexa (С69) does not provide for the distribution of these patients by age, stage and other parameters. State mortality statistics do not provide for the review of the C-69 heading ICD-10. All of this led us to conduct in-depth analysis of the dynamics of morbidity and mortality of eye cancer on the basis of the PRR database of SaintPetersburg. An insignificant increase in the incidence rate of the Russian population of the eye cancer, completely associated with the aging of the population, has been established. Positive increase in the observed and relative survival of patients has been also revealed.
Background. According to a report by the International Agency for Research on Cancer (IARC), lung cancer (LC) is among the leading causes of morbidity and mortality worldwide, with an estimated incidence of 14.1 million new cases of the disease and 8.2 million cancer deaths in 2012. Lung cancer is the most common cancer worldwide, accounting for 13 % of all new cancer cases and 19.4 % of deaths.The purpose of the study was to evaluate LC prevalence and to measure the quality of population-based cancer registries by the indices of the proportion of total incident cases.Material and methods. The study material was given from the monograph «Cancer on Five Continents», which included data from the database of the Cancer Registry of PA. Herzen Moscow Research Oncology Institute (St. Petersburg), surveys of morbidity and mortality in the North-West Federal District, estimations of proportion of the true incidence that was registered in population-based registries.Results. The analysis of lung cancer morbidity and mortality in Russia showed a significant improvement in analytical indices over the past 10 years, however, underestimation of primary cases, reduced the overall lung cancer incidence rate.Conclusions. The dynamics of age-specific lung cancer incidence was shown. The loss of primary lung cancer cases was estimated to be 15-20 % annually.
Background. About 25,000 (2018 - 24,291) new cases of kidney cancer (KC) are registered in Russia annually, in the Northwestern Federal District of Russia in 2018 - 2504.Kidney cancer refers to localizations with a relatively low mortality rate. Mortality in the first year of observation is about 20 %. At the same time, an unfavorable trend in the dynamics of morbidity should be noted. Over the past 10 years, the annual growth rate for both sexes was 3.18%, mortality practically did not change, which indicates certain success in the treatment of patients.Materials and methods. The materials of the research were the monographs of IARC “Cancer on five continents”, reference books of the P.A. Herzen Moscow Oncology Research Institute and the database of the population cancer register of the Northwestern Federal District of the Russia own materials. Standard methods of statistical analysis were used.Results. The study revealed positive trends in the quality of registration of patients with kidney cancer, dynamics of mortality and survival of patients.Conclusion. The positive dynamics of the incidence rate of the population of Russia with kidney cancer has been established, and its place in the world community has been determined. Age-specific levels are close to those in the United States.Particular attention is paid to the need to use the Russian population cancer register database to obtain reliable data for an objective assessment of the activities of the oncological service in relation to kidney cancer.
Злокачественные новообразования (ЗНО) полости носа, среднего уха и придаточных пазух относятся к относительно редко регистрируемым опухолям. Этой проблеме посвящено большое число работ, в основном клинического профиля. Огромный вклад в рещение проблем опухолей головы и шеи внес профессор А.И. Пачес-один из пионеров в организации и развитии этого направления. Его клиническое руководство «Опухоли головы и шеи», переизданное с дополнениями пять
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.